GT201200319A - Derivados de 3, 4-dihidropirrolo [1, 2 -a ] pirazina - 2, 8(1h)- dicarboxamida su preparacion y su uso terapèutico - Google Patents
Derivados de 3, 4-dihidropirrolo [1, 2 -a ] pirazina - 2, 8(1h)- dicarboxamida su preparacion y su uso terapèuticoInfo
- Publication number
- GT201200319A GT201200319A GT201200319A GT201200319A GT201200319A GT 201200319 A GT201200319 A GT 201200319A GT 201200319 A GT201200319 A GT 201200319A GT 201200319 A GT201200319 A GT 201200319A GT 201200319 A GT201200319 A GT 201200319A
- Authority
- GT
- Guatemala
- Prior art keywords
- rent
- group
- cicloalquil
- alquilo
- cicloalquilo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
LOS COMPUESTOS CORRESPONDIENTES A LA FÓRMULA GENERAL (I) EN LA QUE R2 REPRESENTA UN GRUPO ALQUILO C1-10-ALQUILO, C3-10, CICLOALQUIL C3-7-CICLOALQUIL-ALQUILO C1-6-ALQUILO, C1-6-ALQUILO-C3-7-CICLOALQUILO , CICLOALQUILO C3-7-CICLOALQUILO-C3-7-CICLOALQUILO, C1-6-ALQUILTIO-C-1-10-ALQUILO, C1-6-ALCOXI-C1-10-ALQUILO, HIDROXI-ALQUILO C1-10-ALQUILO, HIDROXI-ALQUILO C1 -6-ALQUILO-C3-7-CICLOALQUIL-ALQUILO C1-6-ALQUILO, C3-HIDROXI-10-CICLOALQUILO, ALQUILO C1-10 O CICLOALQUILO C3-FLUOROALQUILO-10-FLUOROCYCLOALQUIL, UN GRUPO HETEROCÍCLICO OPCIONALMENTE SUSTITUIDO, UN GRUPO ALQUILO C1-10-ALQUILO SUSTITUIDO CON UN GRUPO HETEROCÍCLICO OPCIONALMENTE SUSTITUIDOXE REPRESENTA UN GRUPO ELEGIDO ENTRE HIDRÓGENO, FLÚOR, CLORO Y ÁTOMOS DE BROMO O UN GRUPO ALQUILO C1-6-ALQUILO, C3-7-CICLOALQUILO, C3-7-CICLOALQUIL-ALQUILO C1-6-ALQUILO, C1-6-FLUOROALQUILO O CIANO Y R7 REPRESENTA UN GRUPO ARILO TAL COMO FENILO O NAFTILO, OPCIONALMENTE SUSTITUIDO CON UNO O MÁS SUSTITUYENTES, EN FORMA DE LA BASE O DE UNA SAL DE ADICIÓN DE ÁCIDO. EL USO TERAPÉUTICO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1054372A FR2960876B1 (fr) | 2010-06-03 | 2010-06-03 | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201200319A true GT201200319A (es) | 2014-01-17 |
Family
ID=42697541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201200319A GT201200319A (es) | 2010-06-03 | 2012-11-27 | Derivados de 3, 4-dihidropirrolo [1, 2 -a ] pirazina - 2, 8(1h)- dicarboxamida su preparacion y su uso terapèutico |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US8791119B2 (es) |
| EP (1) | EP2588480B1 (es) |
| JP (1) | JP5995841B2 (es) |
| KR (1) | KR20130113928A (es) |
| CN (1) | CN103168041B (es) |
| AR (1) | AR081832A1 (es) |
| AU (1) | AU2011268651B2 (es) |
| BR (1) | BR112012030697A2 (es) |
| CA (1) | CA2801154C (es) |
| CL (1) | CL2012003360A1 (es) |
| CO (1) | CO6602113A2 (es) |
| CR (1) | CR20120595A (es) |
| CY (1) | CY1118512T1 (es) |
| DK (1) | DK2588480T3 (es) |
| DO (1) | DOP2012000296A (es) |
| EA (1) | EA201291364A1 (es) |
| EC (1) | ECSP12012322A (es) |
| ES (1) | ES2603420T3 (es) |
| FR (1) | FR2960876B1 (es) |
| GT (1) | GT201200319A (es) |
| HR (1) | HRP20161494T1 (es) |
| HU (1) | HUE030650T2 (es) |
| IL (1) | IL223364A (es) |
| LT (1) | LT2588480T (es) |
| MA (1) | MA34360B1 (es) |
| MX (1) | MX2012014084A (es) |
| NI (1) | NI201200176A (es) |
| NZ (1) | NZ603947A (es) |
| PE (1) | PE20130259A1 (es) |
| PL (1) | PL2588480T3 (es) |
| PT (1) | PT2588480T (es) |
| SG (1) | SG186143A1 (es) |
| SI (1) | SI2588480T1 (es) |
| TN (1) | TN2012000520A1 (es) |
| TW (1) | TWI487707B (es) |
| UY (1) | UY33428A (es) |
| WO (1) | WO2011161537A2 (es) |
| ZA (1) | ZA201209071B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2960876B1 (fr) * | 2010-06-03 | 2012-07-27 | Sanofi Aventis | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
| TW201605859A (zh) * | 2013-11-14 | 2016-02-16 | 必治妥美雅史谷比公司 | 作為酪蛋白激酶１δ／ε抑制劑之新穎經取代之吡唑并－哌 |
| JP6307989B2 (ja) * | 2014-04-02 | 2018-04-11 | 住友化学株式会社 | 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法 |
| WO2018191389A1 (en) * | 2017-04-12 | 2018-10-18 | Roche Sequencing Solutions, Inc. | A method for sequencing reaction with tagged nucleoside obtained via pictet spengler reaction |
| JP2020528062A (ja) * | 2017-07-27 | 2020-09-17 | 江蘇恒瑞医薬股▲ふん▼有限公司 | ピペラジンヘテロアリール誘導体、その製造方法、およびその医薬での使用 |
| WO2024002157A1 (en) * | 2022-06-29 | 2024-01-04 | Insilico Medicine Ip Limited | Inhibitors of fgfr2 and fgfr3 and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY129445A (en) | 1999-02-01 | 2007-04-30 | Univ Virginia Patent Found | Compositions for treating inflammatory response |
| JP4456365B2 (ja) * | 2001-09-19 | 2010-04-28 | アベンティス・ファーマ・ソシエテ・アノニム | 化合物 |
| GB0202015D0 (en) * | 2002-01-29 | 2002-03-13 | Hoffmann La Roche | Piperazine Derivatives |
| CN100439367C (zh) | 2003-12-11 | 2008-12-03 | 安万特药物公司 | 作为酪蛋白激酶Iε抑制剂的取代的1H-吡咯并[3,2-b、3,2-c和2,3-c]吡啶-2-甲酰胺以及相关类似物 |
| GB0328900D0 (en) | 2003-12-12 | 2004-01-14 | Glaxo Group Ltd | Novel compounds |
| WO2008147713A1 (en) * | 2007-05-24 | 2008-12-04 | The Regents Of The University Of California | Wnt signaling inhibitors, and methods for making and using them |
| DK2185561T3 (da) | 2007-07-27 | 2011-10-10 | Sanofi Sa | Derivater af 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6-carboxamid og 2,3,4,5-tetrahydroprrolo(1,2-a)-diazepin-7-carboxamid, fremstilling deraf og terapeutisk anvendelse deraf |
| JP2011509961A (ja) * | 2008-01-17 | 2011-03-31 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 置換スルホンアミド誘導体 |
| WO2009097515A2 (en) * | 2008-01-30 | 2009-08-06 | Wyeth | [a]-fused indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| FR2960876B1 (fr) * | 2010-06-03 | 2012-07-27 | Sanofi Aventis | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
-
2010
- 2010-06-03 FR FR1054372A patent/FR2960876B1/fr not_active Expired - Fee Related
-
2011
- 2011-06-01 AU AU2011268651A patent/AU2011268651B2/en not_active Ceased
- 2011-06-01 ES ES11781590.2T patent/ES2603420T3/es active Active
- 2011-06-01 JP JP2013513006A patent/JP5995841B2/ja not_active Expired - Fee Related
- 2011-06-01 MX MX2012014084A patent/MX2012014084A/es active IP Right Grant
- 2011-06-01 NZ NZ603947A patent/NZ603947A/en not_active IP Right Cessation
- 2011-06-01 SG SG2012088795A patent/SG186143A1/en unknown
- 2011-06-01 EA EA201291364A patent/EA201291364A1/ru unknown
- 2011-06-01 MA MA35524A patent/MA34360B1/fr unknown
- 2011-06-01 PE PE2012002257A patent/PE20130259A1/es not_active Application Discontinuation
- 2011-06-01 CN CN201180038277.8A patent/CN103168041B/zh not_active Expired - Fee Related
- 2011-06-01 BR BR112012030697A patent/BR112012030697A2/pt not_active IP Right Cessation
- 2011-06-01 DK DK11781590.2T patent/DK2588480T3/en active
- 2011-06-01 CA CA2801154A patent/CA2801154C/en not_active Expired - Fee Related
- 2011-06-01 PT PT117815902T patent/PT2588480T/pt unknown
- 2011-06-01 LT LTEP11781590.2T patent/LT2588480T/lt unknown
- 2011-06-01 PL PL11781590T patent/PL2588480T3/pl unknown
- 2011-06-01 EP EP11781590.2A patent/EP2588480B1/en active Active
- 2011-06-01 KR KR1020127031424A patent/KR20130113928A/ko active Search and Examination
- 2011-06-01 HU HUE11781590A patent/HUE030650T2/en unknown
- 2011-06-01 SI SI201131022A patent/SI2588480T1/sl unknown
- 2011-06-01 WO PCT/IB2011/001594 patent/WO2011161537A2/en active Application Filing
- 2011-06-02 AR ARP110101901A patent/AR081832A1/es not_active Application Discontinuation
- 2011-06-03 UY UY0001033428A patent/UY33428A/es unknown
- 2011-06-03 TW TW100119696A patent/TWI487707B/zh not_active IP Right Cessation
-
2012
- 2012-10-31 TN TNP2012000520A patent/TN2012000520A1/en unknown
- 2012-11-22 DO DO2012000296A patent/DOP2012000296A/es unknown
- 2012-11-26 CR CR20120595A patent/CR20120595A/es unknown
- 2012-11-27 GT GT201200319A patent/GT201200319A/es unknown
- 2012-11-29 IL IL223364A patent/IL223364A/en not_active IP Right Cessation
- 2012-11-29 US US13/688,916 patent/US8791119B2/en not_active Expired - Fee Related
- 2012-11-30 NI NI201200176A patent/NI201200176A/es unknown
- 2012-11-30 ZA ZA2012/09071A patent/ZA201209071B/en unknown
- 2012-11-30 CL CL2012003360A patent/CL2012003360A1/es unknown
- 2012-12-03 CO CO12218640A patent/CO6602113A2/es active IP Right Grant
- 2012-12-03 EC ECSP12012322 patent/ECSP12012322A/es unknown
-
2014
- 2014-07-23 US US14/339,112 patent/US9233965B2/en not_active Expired - Fee Related
-
2016
- 2016-11-11 HR HRP20161494TT patent/HRP20161494T1/hr unknown
- 2016-11-16 CY CY20161101179T patent/CY1118512T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201200319A (es) | Derivados de 3, 4-dihidropirrolo [1, 2 -a ] pirazina - 2, 8(1h)- dicarboxamida su preparacion y su uso terapèutico | |
| CU20140110A7 (es) | Compuestos heterocíclicos como inhibidores de mek | |
| AR094911A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃ | |
| ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
| ECSP12012292A (es) | Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos | |
| AR097931A1 (es) | Derivados de diazacarbazol como ligandos de tau para pet | |
| AR104326A1 (es) | Compuestos nucleósidos 5-sustituidos | |
| AR092269A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| PE20130779A1 (es) | Pirimidinas y triazinas condensadas y su uso | |
| ECSP11010889A (es) | INHIBIDORES DE cMET | |
| AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
| CR9881A (es) | Polimorfos de la sal benzoato de 2-[[6-[(3r)-3amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y metodos de uso para los mismos | |
| PE20130602A1 (es) | Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a | |
| CR8756A (es) | Derivados de acido carboxilico bencimidazolona | |
| BRPI0911422B8 (pt) | compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos | |
| CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
| UY33801A (es) | COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III | |
| CL2010001348A1 (es) | Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad. | |
| CR20150254A (es) | Compuestos quimicos | |
| CR11866A (es) | Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica | |
| CO6230986A2 (es) | Compuesto de 4-piridinona y su uso para cancer | |
| GT200900309A (es) | Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica | |
| CL2008003095A1 (es) | Procedeimiento de preparacion de dihidrotienopirimidas; uno de los compuestos intermediarios considerados; y el procedimiento de preparacion de dicho compuesto intermediario. | |
| HN2009001330A (es) | Compuestos novedosos activos como antagonistas de receptore muscarinico | |
| ECSP11011053A (es) | [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos |